|Over a week ago|
Guardion retains CFA to assist in evaluation of strategic opportunities » 08:3610/0510/05/20
Guardion Health Sciences…
Guardion Health Sciences is providing an update to shareholders with regard to its business plans. In conjunction with Guardion's emphasis on differentiation of brands and the development and integration of an E-commerce platform, and the further development of clinically supported nutritional products and continued expansion into international markets, the Company has retained the investment banking firm of Corporate Finance Associates ("CFA") to act as its exclusive financial advisor to assist management and the Board of Directors in the evaluation of strategic transactions and opportunities to enhance shareholder value. Shortly after recent previously announced changes in senior management, the Board of Directors established a Strategy Committee to work with management and to review the Company's business initiatives, strategies and opportunities in order to maximize shareholder value. As part of that review, the Board of Directors also determined that it would augment the Company's organic growth initiatives with potentially strategic acquisitions to accelerate the development of the Company's core businesses. CFA has been engaged to assist the Company in evaluating complementary products, technologies and businesses that can contribute positively to the Company's top-line revenues and EBITDA. The Company also recently retained CORE IR, a boutique investor and public relations strategic advisory firm, to assist the Company with investor relations, public relations, and shareholder communications services. CORE IR's priority is to focus on expanding market awareness for Guardion and conveying the Company's business model and growth strategies to its shareholders and the investment community. Over the past few months, the Company has been designing and implementing various internal growth strategies which it anticipates, over time, will expand the Company's business platform, product offerings, market position and financial performance with a view to growing the Company and driving shareholder value. These initiatives and strategies include: Portfolio Growth and Brand Focus - Continuing to build out and optimize the Company's core brands, VectorVision and NutriGuard, with its proprietary product lines, such as Lumega-Z, GlaucoCetin, Immune-SF, and the VectorVision CSV-2000 Sales Channel Development: Expand Current B2B Sales Channel - Continuing its work with world-class clinicians, using translational research to focus on new proprietary nutritional research to create new proprietary nutritional strategies. Direct to Consumer - Develop a digital strategy to include a "direct-to-consumer" E-Commerce platform, which the Company believes will provide high leverage opportunities for the distribution of its eligible products. International - Continuing to build and grow its business internationally, particularly in the Far East. Evidence-Based Therapies - Continuing to demonstrate, both clinically and scientifically, through sponsored and investigator initiated research, the efficacy of the Company's condition-specific nutritional therapies. Management Team - Expand and strengthen its management team to include the skills required to execute on the strategies. The Company has not set a timetable for this process and does not intend to disclose developments with respect to this process unless and until the process has been completed, and until it enters into a definitive agreement for a specific material transaction, or as otherwise required by law. The retention of CFA to assist the Company in the exploration and evaluation of strategic transactions or acquisitions may not result in any agreement or transaction and, if completed, any agreement or transaction may not be successful or on attractive terms. In addition, a future transaction may also include a capital raising component to fund expanding business operations and/or to fund acquisitions.
|Over a month ago|
Guardion Health Sciences files $75M mixed securities shelf 15:2309/1809/18/20
Guardion Health product licensee receives registation approval in Malaysia » 08:3308/2708/27/20
Guardion Health Sciences…
Guardion Health Sciences announced that Ho Wah Genting Berhad, a Malaysian company listed on the Malaysian Stock Exchange, has received product registration approval for Astramern Nutra V, an immune support dietary supplement designed and produced by Guardion. The approval of Astramern Nutra V by the Malaysian National Pharmaceutical Regulatory Agency, which is effective through August 21, 2025, represents an important step in HWGB's efforts to market and distribute Astramern Nutra V in Malaysia. In early 2020, HWGB entered into a Manufacturing and Supply Agreement with Guardion for Guardion to design and manufacture two immune support dietary supplements, Astramern Nutra V, a vitamin formulation, and Astramern Nutra H, an herb formulation. HWGB's healthcare subsidiary, Astramern Sdn Bhd, has an exclusive license to use and distribute these products in certain territories. The two products will be packaged together for sale by HWGB in Malaysia. Product registration approval of Astramern Nutra H is pending with the NPRA. Guardion fulfilled HWGB's initial product order of $890,000 in June 2020. Astramern Nutra V is provided in capsule form and includes several important vitamins known to support the immune system and healthy bodily function, most notably N-acetyl-L-cysteine, which helps to replenish cellular glutathione, one of the body's most potent antioxidants.
|Over a quarter ago|
Guardion Health Sciences appoints Andrew Schmidt as VP, CFO » 08:4407/2107/21/20
GHSI, ITI, SMSI
Guardion Health Sciences…
Guardion Health Sciences announced that it has appointed Andrew Schmidt as VP and CFO of the Company. Mr. Schmidt has significant expertise and experience with micro- and small-cap public companies, most recently with Iteris (ITI) and Smith Micro Software (SMSI). As part of the new management team, Mr. Schmidt will be a key participant in the Company's efforts to develop marketing and commercialization strategies for implementation over the next several months, and is expected to provide financial oversight and discipline to the Company's efforts to ramp up ROI-driven sales.
Guardion's VectorVision gets approval for CSV-2000 trademark in South Korea » 09:0907/1507/15/20
VectorVision announced that it has received approval from the Korean Intellectual Property Office in accordance with the Korean Trademark Act to trademark the CSV-2000. The Korean Intellectual Property Office is the national patent and intellectual property office of South Korea. VectorVision's CSV-2000 is the first and only computer vision testing device that provides for standardized contrast sensitivity testing, along with the full range of visual acuity, color, astigmatism, fixation and other vision tests. The VectorVision CSV-2000 is also the only device that contains the AcQviz patented technology for automatically calibrating the monitor light source. AcQviz continuously measures the monitor light level and adjusts the level to 85 cd/m2 - the light level recommended for vision testing by the U.S. National Academy of Science Working Group on Vision Standards, the U.S. Food and Drug Administration and the American National Standards Institute. The AcQviz device is housed in the upper left-hand corner of the screen and communicates via specialized software and miniaturized hardware with the luminance control of the monitor. By incorporating the AcQviz standardization technology with the VectorVision contrast sensitivity test, the CSV-2000 brings true next generation technology to ophthalmic examinations.
Guardion Health Sciences submits patent application to protect GlaucoCetin » 08:4907/0807/08/20
Guardion Health Sciences…
Guardion Health Sciences announced that it has submitted a formal patent application to the U.S. Patent and Trademark Office seeking to protect its proprietary formula, currently marketed by Guardion as GlaucoCetin. GlaucoCetin provides nutritional support to help manage certain underlying conditions related to eye disease. The company previously submitted a provisional patent to the U.S. Patent and Trademark Office on June 11, 2019. The invention relates to a nutritional formula designed to reverse mitochondrial dysfunction in nerve cells.
Guardion Health Sciences names David Evans interim president, CEO » 16:2106/1506/15/20
Guardion Health Sciences…
Guardion Health Sciences announced that its Board of Directors has appointed Dr. David Evans, Ph.D. as the company's Interim President and Interim Chief Executive Officer effective immediately. Dr. Evans has served as the company's Chief Science Officer and was the founder of the company's subsidiary, VectorVision. Dr. Evans joined the Guardion Board of Directors effective with the Company's acquisition of VectorVision on September 29, 2017. David Evans succeeds Michael Favish, who is the founder of Guardion and who is stepping down as an officer and employee of Guardion and is also leaving the Board of Directors of Guardion. The Board is conducting an extensive search to identify the company's next Chief Executive Officer and will provide additional information to shareholders as it becomes available.
Guardion Health Sciences reports Q1 revenue $245,723 vs. $242,538 last year » 07:4505/1405/14/20
"We are pleased with…
"We are pleased with the progress made over the first quarter of 2020. We continued to execute strategically and were able to maintain total revenue, with a slight 1% increase, compared to the same period of last year, despite the current coronavirus pandemic. While our medical device sales slowed due to doctor office closures as a result of government mandated stay-at-home orders that commenced in March, we were able to offset this by a 40% increase in our medical foods revenue. We are also executing on our vision to include nutraceuticals in our product portfolio through the NutriGuard brand," commented Michael Favish, CEO of Guardion. "Additionally, in April, we launched acuMMUNE, a proprietary immuno-supportive complex designed with the objective of supporting effective immune function and received an initial order for $875,000 from Astramune Sdn Bhd, a subsidiary of Ho Wah Genting Berhad, a Malaysian company listed on the Malaysian Stock Exchange. As we look forward to the remainder of the year, we intend to continue building out our online medical foods distribution channels which were bolstered by our acquisition of NutriGuard last year. Direct-to-consumer sales not only has the potential to benefit users by providing an easy way to access our products, but also helps to diversify our business from solely relying on distribution through doctors' offices, while introducing subscription-based recurring revenue generation."
Guardion says Lumega-Z demonstrates superiority in head-to-head study » 07:0805/1205/12/20
Guardion Health Sciences…
Guardion Health Sciences announced the publication of study data comparing the efficacy of the Company's micronized liquid formula Lumega-Z, to the current standard AREDS 2 soft gel supplement. Results from the study concluded that Guardion's unique, proprietary formulation, Lumega-Z, provided significantly higher blood concentration levels of carotenoids, which have been shown by studies sponsored by the National Eye Institute to be important for slowing the progression of macular degeneration in certain patients, and the MPOD, which has been shown in studies to be an important and modifiable biomarker to track the progression of macular degeneration and other eye diseases. Lumega-Z, the Company's proprietary medical food, is the only micronized lipid-base nutritional formulation designed to restore a depleted macular pigment. This unique delivery platform ensures the highest level of absorption as well as rapid patient response to treatment. Participants in the study were given a 24-week supply of a lipid-based micronized liquid medical food, Lumega-Z, containing 28 mg of the macular carotenoids lutein, zeaxanthin and meso-zeaxanthin, or given PreserVision AREDS 2 Formula containing 12 mg of the macular carotenoids L and Z, but no reported MZ. Serum levels of L, Z and MZ were obtained at baseline and after 12 weeks. Macular pigment optical densities and visual function were assessed at baseline and after 24 weeks. Results from the study were recently published in the peer-reviewed journal, Nutrients, titled, "Efficacy of Commercially Available Nutritional Supplements: Analysis of Serum Uptake, Macular Pigment Optical Density and Visual Functional Response."
JTC Investor Relations + Integrated Communications to hold virtual summit » 04:5504/2304/23/20
AEZS, AREC, COCP, GHSI, MTNB, OTLK, TFFP, XBIO
Virtual Investor Summit…
Virtual Investor Summit will be held at 10 am on April 22-23. Webcast Link